Maternal health company Nua Surgical secures €6.5m for C-Section retractor

Nua Surgical, an Irish medical device company focusing on maternal health has secured €6.5m that will be used to drive the manufacturing, testing, regulatory clearance and early commercialisation of its C-Section retractor.

The device has been designed to address the unique challenges of C-Section surgery. Caesarean sections are the most common major surgical procedure globally, with over 30 million performed each year.

The SteriCISION C-Section retractor is a self-retaining surgical retractor designed to provide fast, adjustable, and safe retraction, enabling clinicians to deliver the baby, repair tissue, and identify bleeds.

As a single-use sterile device, it aims to reduce the risk factors that lead to surgical complications.

The new investment will support Nua Surgical’s next phase of development and the device’s early commercialisation, as well as expanding the team, establishing manufacturing in Ireland, and meeting the regulatory requirements necessary to gain FDA clearance.

Barry McCann, CEO of Nua Surgical, said: “Securing this Series A financing is a crucial milestone for Nua Surgical.

“It not only provides the capital needed to advance our product but also brings on board a group of experienced investors who share our vision for transforming maternal health. We are eager to leverage their expertise as we move towards commercialising SteriCISION.”

“Nua Surgical’s SteriCISION C-Section Retractor has the potential to significantly enhance
outcomes for mothers undergoing C-Section procedures,” said Anne Portwich, partner at investor EQT.

“We are excited to support the company’s journey towards market entry. This innovative device shows promise in potentially improving the quality of care and reducing healthcare costs, making it a perfect fit for our EQT Health Economics strategy.”